Impact of the COVID-19 Pandemic on Central Precocious Puberty: a Retrospective Cohort Study from Turkey

Objective: This study investigates the clinical and demographic characteristics of girls diagnosed with central precocious puberty (CPP) in the pre-pandemic and pandemic periods to assess potential changes during the COVID-19 pandemic.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID19- Infection with SARS-CoV-2 Virus COVID-19 Coronaviridae Infections Coronavirus Infections Endocrine System Diseases Gonadal Disorders Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral Puberty, Precocious RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

Up to 18 year

Sex eligibility

Female

Study type

Observational

Primary location

the Pediatric Endocrinology Departments of Umraniye Training and Research Hospital

Istanbul, 34764, Turkey (Türkiye)

About this study

Methods: A retrospective cohort study was conducted on patients admitted to the Pediatric Endocrinology Departments of two centers in Turkey. Girls treated with GnRH analogs between March 2018 and 2022 were categorized into two groups: the pre-pandemic group (2018-2020) and the pandemic group (2020-2022). Clinical, anthropometric, and hormonal data were analyzed. Patients with organic lesions, genetic conditions, or medications affecting puberty were excluded.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(Who Can Participate?)

Girls: Tanner stage ≥2 before age 8 peak LH > on gnrh analog test, basal Lh >0,3

Patients with organic lesions (e.g., hypothalamo-pituitary tumors), congenital malformations, oncological diseases, neurosurgical or genetic disorders, or medications affecting puberty were excluded from the study

Treatment and study plan

Primary outcomes

Mean Age at Pubertal Onset

Time frame: 4 years

Mean Age at Pubertal Onset

Description: The mean age at pubertal onset will be compared between pre-pandemic and post-pandemic periods in both girls and boys.

Time Frame: At baseline. Method of Measurement: Tanner staging, LH/FSH levels, and bone age assessment.

Sponsors and collaborators

Lead sponsor

Umraniye Education and Research Hospital

Other Gov

Registry information

Acronym: COVID-19-PP

Important dates

Study start: 2018
Primary completion: 2022
Study completion: 2023
First posted: Feb 12, 2025
Registry last updated: Feb 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed